Tasigna

DRUG5 trials

Sponsors

Novartis Pharmaceuticals, Centre Leon Berard, Indiana University, XSpray Microparticles

Conditions

All Indications for Glivec/Gleevec and TasignaChronic Myeloid LeukemiaHealthyNF1NeurofibromasNeurofibromatosisPigmented Villonodular Synovitis

Early Phase 1

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

CompletedNCT01275586

Indiana UniversityNeurofibromas, Neurofibromatosis, NF1

Start: 2011-01-31End: 2016-10-31Updated: 2017-04-12

Phase 1

To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

CompletedNCT01223898

Novartis PharmaceuticalsChronic Myeloid Leukemia

Start: 2010-06-30End: 2013-12-31Updated: 2020-12-09

Pharmacokinetic Comparison of XS003 and Tasigna

CompletedNCT02068898

XSpray MicroparticlesHealthy

Start: 2013-12-31End: 2014-05-31Updated: 2014-11-11

Phase 2

Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)

CompletedNCT01261429

Centre Leon BerardPigmented Villonodular Synovitis

Start: 2010-12-31End: 2013-04-30Updated: 2013-04-16

Unknown Phase

A Global Imatinib and Nilotinib Pregnancy Exposure Registry

CompletedNCT01289054

Novartis PharmaceuticalsAll Indications for Glivec/Gleevec and Tasigna

Start: 2011-01-31End: 2015-03-31Updated: 2015-04-15

Related Papers

Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT.

2022-08-0324 citations

Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial.

2018-03-2087 citations